Health
Ramaswamy Has a High-Profile Perch and a Raft of Potential Conflicts

Vivek Ramaswamy is the less famous and less wealthy half of the duo of billionaires that President-elect Donald J. Trump has designated to slash government costs.
His better-known co-leader, Elon Musk, stands to benefit from the job in ways that are numerous and glaring. Mr. Musk’s companies have tremendous influence, billions of dollars in government contracts and ongoing battles with federal regulators.
Less attention has been paid to the potential conflicts that could stem from Mr. Ramaswamy’s complex web of financial interests, which span biotechnology, finance and other holdings.
At 39, he is one of the world’s youngest billionaires, having made his fortune in the pharmaceutical industry. As he reaches into the federal bureaucracy that shapes the fortunes of American companies, he could recommend spending cuts that ultimately make him and his investors richer.
Mr. Ramaswamy, who owns a stake currently valued at nearly $600 million in a biotechnology company he started, has called for changes at the Food and Drug Administration that would speed up drug approvals. He could help shape energy policy to promote fossil fuels, making it more attractive for investors to put their money into an oil-and-gas fund, provocatively called DRLL, offered by his investment firm.
And if he were to boost officials who embrace cryptocurrency, it may benefit his firm’s new Bitcoin business.
It is not yet known whether leaders of the so-called Department of Government Efficiency, or DOGE, which is not a governmental department but more of an outside advisory organization, will have to meet the same standard divestment requirements that many high-level federal appointees face.
Mr. Ramaswamy waded into controversy late last month when he blamed American culture for failing to produce enough workers suited for technical jobs. He also endorsed continuing to allow certain skilled immigrants into the U.S. labor market, a position shared by Mr. Musk and Mr. Trump but opposed by immigration hard-liners. The episode raised questions as to how long Mr. Ramaswamy will remain with the DOGE effort.
Mr. Ramaswamy, who two years ago stepped away from running his businesses, declined to say whether he plans to divest from any of his holdings.
With a stake valued at $150 million or more, he is the majority owner of his investment fund, Strive Enterprises, which he branded as a nemesis of liberal politics, and which is suddenly in line with the philosophies now ascendant in Washington. Several of Strive’s financial backers have close ties to the incoming Trump administration.
Investment funds like Strive generate revenue as a percentage of the money they manage. Luring new investors quickly raises the revenues of the firm. Mr. Ramaswamy’s elevated profile advising the Trump administration could help the firm bring in new clients.
Mr. Ramaswamy declined to be interviewed for this article. Strive’s current leadership, Mr. Musk and the Trump transition team also declined to comment.
Anson Frericks, a high school friend of Mr. Ramaswamy’s who co-founded Strive with him and is now a senior adviser at the firm, dismissed concerns about potential conflicts of interest for a firm offering investments in industries under federal regulation.
“We will always have to have a strict separation of church and state and comply with all the rules and regulations,” Mr. Frericks said.
Since being named to jointly lead DOGE, Mr. Ramaswamy had until recently been posting on Mr. Musk’s social media site X, hinting about where he may look to make changes in the government.
He called for slashing regulation, not just cutting government spending. He pointed to federal workers focused on diversity as potential targets for “mass firings.”
And he has been taking aim at the F.D.A. “My #1 issue with FDA is that it erects unnecessary barriers to innovation,” he wrote on X. He criticized the agency’s general requirement that drugmakers conduct two successful major studies to win approval rather than one.
Mr. Ramaswamy founded his biotechnology company, Roivant Sciences, in 2014, betting that he could find hidden gems whose potential had been overlooked by large drugmakers. The idea was to hunt for experimental medications languishing within large pharmaceutical companies, buy them for cheap and spin out a web of subsidiaries to bring them to market.
The venture is best known for a spectacular failure.
In 2015, Mr. Ramaswamy whipped up hype and investment around one of his finds, a potential treatment for Alzheimer’s disease being developed by one of his subsidiaries, Axovant. Two years later, a clinical trial showed that it did not work, erasing more than $1.3 billion in Axovant’s stock value in a single day.
Mr. Ramaswamy personally lost money on paper on the failure, but thanks to the savvy way he had structured his web of companies he and Roivant weathered the storm. Six products have won F.D.A. approval, and today Roivant has a market valuation of $8 billion.
Mr. Ramaswamy sold some of his Roivant stock to take a large payout in 2020, reporting nearly $175 million in capital gains on his tax return that year. But he is still one of the company’s largest shareholders.
If Mr. Ramaswamy recommends changes that speed up drug approvals through DOGE, that could be good news for Roivant, which is developing drugs that might come up for approval during Mr. Trump’s second term. The faster it can get medicines onto the market, the more valuable the company — and Mr. Ramaswamy’s stake in it — stands to become.
Fighting ‘woke’
In 2020, Mr. Ramaswamy started writing opinion pieces attacking the environmental, social and governance, or E.S.G., movement.
He found a perfect foil in the world’s biggest asset manager, BlackRock, and its chief executive, Laurence D. Fink. At the time, Mr. Fink was vocal about pushing companies to rethink their carbon footprints. Mr. Ramaswamy viewed that position as a breach of BlackRock’s duty to try to maximize returns for investors.
Mr. Ramaswamy was taking on a niche subject that was being debated in obscure journals and business school classrooms but one that was hardly front of mind for most investors.
In July 2020, Mr. Ramaswamy asked D.A. Wallach, a health care investor, to read a proposal for what would become his first book, “Woke, Inc.” Mr. Wallach said he was initially skeptical.
“Do average people really care about Larry Fink putting carbon emissions requests on the board of Exxon?” Mr. Wallach recalled wondering at the time. But Mr. Wallach later became a seed investor in Strive, persuaded by Mr. Ramaswamy over dinner at the upscale Polo Lounge at the Beverly Hills Hotel in Southern California.
In 2021, Mr. Ramaswamy stepped down as chief executive of Roivant. He fished around for a new business idea.
A classmate of Mr. Ramaswamy’s from an all-boys Catholic high school in Cincinnati, Mr. Frericks, had worked as an executive at Anheuser-Busch and shared Mr. Ramaswamy’s views about the E.S.G. movement.
Mr. Frericks said they knocked several ideas around: “Merit Airlines,” which would hire the top 5 percent of pilots, regardless of race, sex or background; “Pop Without Politics,” an alternative to Coca-Cola; and a “free-speech” version of Twitter, before Mr. Musk ran with the idea and bought the social media platform.
They ultimately landed on a different idea. They would start an investment firm near Columbus, Ohio, that would court an audience they believed had been neglected by Wall Street: everyday investors and public pension fund managers who were alienated by companies adopting liberal policies pushed by money managers like Mr. Fink.
Mr. Ramaswamy recruited financial backers who now have deep ties to the incoming Trump administration. Among them were Howard Lutnick, whom Mr. Trump has picked to be commerce secretary; the former investment firm of Vice President-elect JD Vance; and other large Republican donors and influential voices, including Doug Deason and the billionaire fund manager Bill Ackman.
Releasing the handcuffs
Strive’s first offering, in August 2022, was the energy fund DRLL.
In television appearances, Mr. Ramaswamy drummed up demand for the fund. He pitched viewers on an opportunity to be part of a renaissance in the American energy sector, which he said had been constrained for too long by “E.S.G. handcuffs.”
The reality was more complicated. Energy stock price growth has been sluggish for reasons that have nothing to do with diversity quotas and emissions caps. For years, U.S. producers spent big in pursuit of growth, costing investors billions and causing many to sour on the industry. Lower oil prices have further reduced the incentive to drill.
And what Mr. Ramaswamy was pitching was more commonplace than he made it sound.
DRLL was a basket of stocks known as an exchange-traded fund, or an E.T.F., an unglamorous investment vehicle that has grown popular among investors looking for less risk than betting on individual stocks. Mr. Ramaswamy’s E.T.F. was nearly identical to popular offerings from BlackRock and other providers, containing a standard mix of stocks like Exxon, Chevron and dozens of other oil and gas companies.
What Strive promised investors in DRLL was essentially a sustained pressure campaign. Strive would meet with chief executives, carefully vote on board seats and shareholder proposals and publicize its efforts, all with the aim of pushing energy companies to shun liberal policies.
“We wanted a seat at the table, to be able to vote on shareholder resolutions, to engage with management, write letters on our views,” Mr. Frericks said.
Mr. Ramaswamy sent an angry letter to Chevron, criticizing the company for how it responded to pressure from climate activists to cap emissions produced by its suppliers and consumers. (Chevron set goals related to how clean those emissions should be, but it didn’t limit them overall.)
In November 2022, Mr. Ramaswamy flew to Houston for a meeting with the Exxon chief executive, Darren Woods. When the oil giant subsequently appointed two Strive-approved board members, Strive declared victory.
As a presidential candidate in mid-2023, Mr. Ramaswamy reported that he had between $5 million and $25 million of his own money invested in DRLL.
From C.E.O. to candidate
Strive employees watched with intrigue, and sometimes tagged along, as Mr. Ramaswamy met with governors, other state officials and wealthy contacts. Often, it wasn’t clear whether the motivation was to seek an investment or perhaps to make connections that could fuel Mr. Ramaswamy’s bigger ambitions.
He set a busy pace, using private jets to crisscross the United States and traveling with a body guard. He hated staying in hotel rooms, so if he traveled he would nearly always fly home to sleep.
He met with heads of public pension funds in Republican-led states, urging them to move their money to Strive from providers like BlackRock.
But Strive’s pitch struggled to land with that audience. According to S&P Global’s Capital IQ database, only one public pension fund, in Texas, appears to have put money in a Strive E.T.F., and it quickly withdrew its position. One official at a public pension fund in a Republican-led state who met with a Strive representative said it was confusing how Strive was different from the competition, or how its mission would generate the best returns.
Employees at Strive were often surprised by the relative extravagance of Strive’s spending.
Before the firm was generating much revenue, many employees were issued a company credit card and had the impression that they could spend freely. The firm built out a new office, with room for some 100 employees, despite having a staff of about 35.
Mr. Ramaswamy was a regular presence in Strive’s office, often dressed in shorts and flip flops.
In December 2022, the firm held a holiday party in downtown Columbus at The Vault, a former bank repurposed as a lavish event space. In front of his delighted colleagues that evening, Mr. Ramaswamy performed a karaoke rendition of Eminem’s “Lose Yourself.”
Employees were given a pointed holiday gift: a copy of a book, “Fossil Future” by Alex Epstein, arguing for more oil, coal and natural gas consumption.
Two months later, Mr. Ramaswamy announced that he was running for president. He stepped down as chairman and chief executive of Strive. That summer, as a candidate on the campaign trail, he reprised his performance of “Lose Yourself” onstage at the Iowa State Fair.
A crypto arm
As Mr. Ramaswamy’s political profile has risen, the ideas he railed against have receded on Wall Street and in American life.
In 2023, Mr. Fink of BlackRock said that he would no longer use the term E.S.G. Last week, BlackRock pulled out of an international climate coalition supporting the goal of net zero greenhouse gas emissions by 2050, while Meta and Amazon ended internal diversity programs.
Mr. Ramaswamy has taken credit for the change of heart. “Strive’s success, I think, was probably the single greatest factor in the United States of America that turned E.S.G. from the dogma,” he said.
Today, Strive manages over $2 billion in assets, a strong start for a new player in the market, but a drop in the bucket compared with the largest money managers. BlackRock, by comparison, manages $11.6 trillion in assets.
“Strive did better than we thought it would,” said Eric Balchunas, a Bloomberg analyst who tracks E.T.F.s.
But the growth of Strive, which in some cases charges higher fees than its competitors for its E.T.F.s, has been constrained by a mundane reality: Many E.T.F. investors are just looking for low fees and the ability to swiftly and easily make transactions. Politics isn’t a factor.
“Most of them don’t care,” Mr. Balchunas said. “People just want cheap access to stocks.”
After years in the unglamorous world of traditional E.T.F.s, Strive has been expanding into a more buzzy world of finance after raising $30 million in new funding from a group of backers including Cantor Fitzgerald, the financial services firm led by Mr. Lutnick.
Late last year, Strive poached the leadership team of a firm in Dallas that managed money for wealthy families and individuals, providing Strive a new arm, and a new headquarters, in Texas.
The move got Strive into cryptocurrency, which helped finance Mr. Trump’s campaign but has faced regulatory headwinds in Washington. The firm’s website now points to its “focus as a transformative Bitcoin-company.”
It also opened up a new potential area for conflict in Mr. Ramaswamy’s role at DOGE: the potential power to alter the approach of agencies that regulate the financial sector.

Health
Video: Trump Pushes Unproven Link Between Tylenol and Autism

new video loaded: Trump Pushes Unproven Link Between Tylenol and Autism
By Azeen Ghorayshi, Claire Hogan, Theodore Tae and June Kim•
Top U.S. health officials urged pregnant women not to use acetaminophen, the active ingredient in Tylenol, claiming it could cause autism, though studies have been inconclusive. Azeen Ghorayshi, a science reporter for The New York Times, explains.
Health
Autism by the numbers: Experts share reasons for the dramatic surge in diagnoses

NEWYou can now listen to Fox News articles!
Monday’s sweeping autism announcements have sparked deeper conversations about the widespread neurological disorder.
Health officials spoke during a press conference in Washington, D.C., about possible causes, vaccine guidance and the potential for a cancer drug to double as an autism therapy.
Autism diagnoses have been steadily rising in recent decades, according to the Centers for Disease Control and Prevention.
AUTISM SPECTRUM IN ADULTS HAS COMMONLY OVERLOOKED SYMPTOMS, EXPERTS WARN
“In the 1970s, autism was considered rare, perhaps 1 in 5,000 to 10,000 children,” Steven Quay, M.D., Ph.D., a physician-scientist and founder of Atossa Therapeutics in Seattle, Washington, told Fox News Digital.
In the year 2000, an estimated one in 150 children aged 8 had the disorder. By 2010, that number had risen to one in 68 — and by 2022, one in 31 children were diagnosed.
Autism diagnoses have been steadily rising in recent decades, according to the Centers for Disease Control and Prevention. (iStock)
“Autism is no longer an uncommon condition tucked away in psychiatric textbooks,” said Quay. “It is part of the daily fabric of schools, clinics and families everywhere.”
Dr. Aggie Papazyan, a Los Angeles-based psychologist specializing in autism spectrum disorder, noted that autism prevalence has also increased globally.
CANCER DRUG COULD DOUBLE AS AUTISM THERAPY, AND IS POISED FOR FDA APPROVAL
“These rates vary by region,” she told Fox News Digital. “In many places, especially in higher-income settings with more robust diagnostic and health resources, prevalence estimates have gone up.”
She added, “However, it’s important to note that how autism is measured makes a big difference.”
Awareness vs. epidemic
The CDC has noted that improved identification of autism could be part of the increase, but that other factors could also come into play.
Decades ago, many autistic people were “missed, misdiagnosed or labeled differently,” said Papazyan.
“There doesn’t seem to be a sudden surge in biological incidence.”
“Over time, as awareness has grown, diagnostic definitions expanded and screening became a bit more routine — so it’s not a surprise to see more autism diagnoses,” she said.
“The biggest misconception is that rising numbers mean autism itself is suddenly becoming more common,” the expert went on. “That’s scary to some people, but there’s no new autism ‘epidemic.’”

Experts say more funding is needed for early intervention programs, such as speech, occupational and behavioral therapies. (iStock)
Most of the increase, according to Papazyan, is due to earlier intervention, broader diagnostic criteria and improved access to services.
“There doesn’t seem to be a sudden surge in biological incidence,” she added. “There may still be a true rise, but it’s not as dramatic as many people want to think.”
Quay said it would be “naïve” to assume that the rise is due only to better detection, and said that environmental change also plays a role.
“Fifty years ago, many individuals on the spectrum were mislabeled — sometimes as intellectually disabled, sometimes as ‘eccentric’ or ‘odd,’ but I do not believe this accounts for the entire increase,” he said.

To counter the rising autism diagnoses, experts call for increasing awareness and acceptance while reducing stigma. (iStock)
“Environmental influences, from prenatal exposures to changes in maternal health to shifts in early childhood experiences, likely play some role.”
‘Urgent need’
To counter the rising autism diagnoses, Papazyan is calling for increasing awareness and acceptance while reducing stigma, as this affects how resources are allocated.
“Beyond that, we need to expand diagnostic and assessment services, especially in underserved communities, so that people are properly diagnosed and given the care they need,” she said.
Papazyan said more funding is also needed for early intervention programs, such as speech, occupational and behavioral therapies.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The experts also agreed that support is needed for autistic people as they get older, including mental health services, financial assistance and life skills development.
“Interventions are needed that go beyond childhood, because autistic adults will spend most of their lives outside the school system, yet services for them are almost nonexistent,” said Quay.
“Fifty years ago, many individuals on the spectrum were mislabeled.”
Looking ahead, Papazyan predicts that autism prevalence will continue to increase over the next few years before it slows down and eventually hits a plateau.
Quay also expects that prevalence will continue to rise in the near term, largely due to improvements in detection and “societal willingness to diagnose.”
For more Health articles, visit www.foxnews.com/health
“Whether there is a biological plateau remains to be seen,” he said. “If environmental contributors are identified and mitigated, we could see stabilization.”
Health
Who Makes Vaccine Policy Decisions in RFK Jr.’s Health Department?

For decades, as an activist, Robert F. Kennedy Jr. resisted the scientific consensus that vaccines are safe and necessary to prevent serious disease. Now at the helm of the nation’s health department, he has begun to put his extreme views into practice, ousting veteran scientists and installing allies across the nation’s health agencies to enact major shifts in vaccine policy.
Some of Mr. Kennedy’s hires are activists who have worked for years alongside him. Others are scientists who say they broadly support vaccines but publicly criticized Covid shots or mandates during the pandemic. Many of these scientists have begun to question the safety or value of other shots, reflecting the views of Mr. Kennedy. The following account is based on previous statements made by these officials and on interviews with current and former health agency leaders.
F.D.A. chief medical and scientific officer
Critical of Covid boosters and shots for healthy kids
F.D.A. commissioner
Skeptical of certain vaccines
Dr. Vinay Prasad
Dr. Marty Makary
The agency’s new vaccine lead and chief medical officer, Dr. Vinay Prasad, has called himself an “extreme pro-vaccine person,” and Dr. Marty Makary, the agency’s commissioner, said last week that “we believe in vaccines.”
But the two officials, who sharply criticized vaccine mandates as academic researchers during the pandemic, have expressed doubts about the safety and necessity of Covid boosters for healthy children and adults. This summer, Dr. Prasad overrode some agency scientists who favored widespread access to Covid shots, narrowing the vaccine’s eligibility to those 65 and older and to younger people with underlying medical conditions.
Last week, Dr. Makary echoed the views of Mr. Kennedy when he publicly questioned the longstanding recommendation to give the hepatitis B vaccine at birth. That shot is credited with nearly eliminating the transmission of the disease from mother to infant.
Dr. Prasad replaced a veteran at the agency, Dr. Peter Marks, who resigned in March and said that Mr. Kennedy’s aggressive stance on vaccines posed a danger to the public.
In June, Mr. Kennedy fired all 17 members of a powerful C.D.C. expert panel, the Advisory Committee on Immunization Practices. Insurance companies and government programs like Medicaid are required to cover the vaccinations that the panel recommends.
Mr. Kennedy handpicked eight new members that month, half of whom had expressed skepticism of vaccines at some point. (One has since stepped down.) Others have little expertise in immunology or vaccines.
On Monday, Mr. Kennedy appointed five more members, just days before the group meets to review recommendations for multiple vaccines. Some of the newly selected members have been critical of Covid vaccines or vaccine mandates.
Dr. Robert Malone is a controversial figure. He performed early experiments using mRNA in the 1980s but gained notoriety during the pandemic for claiming that Covid vaccines were unsafe, contradicting volumes of studies.
Martin Kulldorff, a biostatistician, has been generally supportive of vaccines but opposed Covid vaccination for children and vaccine mandates. Vicky Pebsworth, a nurse with a doctorate in public health, serves on the board of the National Vaccine Information Center, a nonprofit that disseminates misinformation about the risks of vaccination.
Dr. Malone and Dr. Kulldorff have served as paid expert witnesses in legal cases against vaccine makers. Dr. Pebsworth claimed in a lawsuit that a survey of families of unvaccinated children supported a hypothesis that a rise in the number of recommended childhood vaccines explained an epidemic of chronic disease.
Another panel member, Retsef Levi, is a management and health analytics expert at the Massachusetts Institute of Technology. He has been critical of a variety of vaccines and has called for Covid vaccines to be pulled from the market.
Dr. Evelyn Griffin, an obstetrician and gynecologist, questioned the safety and effectiveness of Covid vaccines in a hearing in the Louisiana House of Representatives in 2021. Dr. Kirk Milhoan, a pediatric cardiologist, questioned the safety and effectiveness of Covid vaccines at a 2024 event led by Representative Marjorie Taylor Greene, Republican of Georgia. Catherine M. Stein is an epidemiology professor who in 2022 called for an end to Covid vaccine mandates at universities.
Dr. Cody Meissner is a professor of pediatrics who opposed vaccine mandates and has questioned the ongoing need for Covid vaccines for children and pregnant women. He previously served on the advisory committee and is widely considered to be the most qualified member.
The others are not known to have spoken out against vaccines. They are Dr. Joseph R. Hibbeln, a nutritional neuroscientist; Dr. James Pagano, an emergency medicine physician; Hillary Blackburn, a pharmacist; and Dr. Raymond Pollak, a surgeon and transplant specialist.
The C.D.C. director has the power to accept or reject the immunization committee’s recommendations. The current acting director is Mr. Kennedy’s deputy at the Department of Health and Human Services, Jim O’Neill, a former biotechnology executive. The previous director, Susan Monarez, said she was forced out because she would not agree to accept the newly re-formed committee’s recommendations.
A special adviser to the C.D.C. director, Stuart Burns, is a critical player driving the health secretary’s agenda at the agency. Mr. Burns has been quietly working to remake the immunization committee and its agenda.
Mr. Burns is not a scientist but he worked for decades as a staff member for Republican congressmen known for their vaccine skepticism. One is Dr. Dave Weldon, a former representative from Florida who was also Mr. Kennedy’s original choice for C.D.C. director. The White House withdrew Dr. Weldon’s nomination just hours before his confirmation hearing because some Senate Republicans were concerned about his stance on vaccines.
Mr. Burns works closely with three other Kennedy hires who serve H.H.S. but also work closely with the C.D.C. Dr. Reyn Archer is a former Texas health commissioner who has questioned the safety and value of the Covid vaccine on social media. He serves as a liaison between the health secretary’s office and the C.D.C., and has been helping Mr. Burns to develop and guide the immunization committee.
David Geier is a steadfast figure in the anti-vaccine movement who has spent more than 20 years trying to establish a link between vaccines and autism, despite scientific consensus that there is none. Mr. Geier, who is listed as a senior data analyst in the H.H.S. directory, was given access to federal data on post-vaccination side effects and is using it to continue his studies on autism.
Lyn Redwood is a nurse practitioner and the former head of Children’s Health Defense, the anti-vaccine group founded by Mr. Kennedy. Since the early 2000s, Ms. Redwood has criticized the use of mercury as a preservative in vaccines. She has said she believes the ingredient is linked to her son’s autism.
Now listed as an expert at H.H.S., Ms. Redwood gave a presentation in June to the immunization committee, a role usually reserved for C.D.C. scientists. She said that the mercury preservative in vaccines, known as thimerosal, was toxic to children, even though dozens of studies have shown it is harmless in this form. The panel later voted to stop recommending the already limited number of flu vaccines that contained the preservative.
Principal deputy director of the N.I.H.
Skeptical of certain vaccines
N.I.H. director
Critical of Covid vaccine mandates
Dr. Matthew Memoli
Dr. Jay Bhattacharya
Dr. Matthew Memoli is a veteran infectious disease scientist at the National Institutes of Health who now serves as its principal deputy director. As a senior researcher under Dr. Anthony Fauci during the pandemic, Dr. Memoli opposed Covid vaccine mandates and declined to get a shot himself.
Since becoming a leader of the research agency, Dr. Memoli has downplayed the value of vaccines for certain respiratory diseases, according to the whistle-blower complaints of two prominent scientists.
Dr. Jay Bhattacharya, the N.I.H director, sharply criticized vaccine mandates as an academic researcher during the pandemic. He co-wrote an anti-lockdown treatise in 2020 with Dr. Kulldorff, one of Mr. Kennedy’s selections for the C.D.C. immunization committee.
During his confirmation hearing in March, Dr. Bhattacharya reiterated his support for childhood vaccinations for diseases like measles. He also said he was “convinced” vaccines did not cause autism, even as he urged more research on the question, which scientists say has long been settled.
-
Finance6 days ago
Reimagining Finance: Derek Kudsee on Coda’s AI-Powered Future
-
Business1 week ago
How Nexstar’s Proposed TV Merger Is Tied to Jimmy Kimmel’s Suspension
-
North Dakota6 days ago
Board approves Brent Sanford as new ‘commissioner’ of North Dakota University System
-
World1 week ago
Russian jets enter Estonia's airspace in latest test for NATO
-
Crypto5 days ago
Texas brothers charged in cryptocurrency kidnapping, robbery in MN
-
World5 days ago
Syria’s new president takes center stage at UNGA as concerns linger over terrorist past
-
Technology5 days ago
These earbuds include a tiny wired microphone you can hold
-
Culture5 days ago
Test Your Memory of These Classic Books for Young Readers